… value of pretreatment serum CYFRA 21–1 values (PCV) in patients with surgically treated
lung … CYFRA 21–1 on the prognosis of untreated advanced lung adenocarcinoma patients. …

… serum CYFRA 21-1 level on NSCLC survival. The herein meta-analysis confirms this
literature analysis and allows a precise estimation of the hazard ratio related to the marker. The …

… level of CYFRA 21-1 is associated with shorter OS in patients with … that CYFRA 21-1 is a
predictive marker of PFS in patients with … An elevated serum level of CYFRA 21-1 has also been …

… Results: With a median follow-up of 86 months for surviving patients, those with initial
Cyfra21-1 serum levels higher than 3.57 ng/ml had a significantly worse prognosis (P=0.014). The …

… and a ≥25% reduction in CEA were significant prognostic factors for better overall survival.
The median overall survival time in patients with a ≥60% reduction in CYFRA21-1 was …

… In conclusion, CYFRA 21-1 is a tool available to predict the survival of NSCLC patients
receiving gefitinib as … In conclusion, CYFRA 21-1 is a tool available to predict survival of NSCLC …

… evaluated serum CYFRA21-1 levels in NSCLC patients with … patients who have elevated
pretreatment serum CYFRA21-1 … to determine pretreatment serum CYFRA21-1 levels that can …

… among patients … patients with a serum CYFRA 21-1 level of ≥2.2 ng/mL was 5.2 months.
This result was similar to the median PFS of patients in a recent phase III trial who exhibited >1%…

… For patients with high CEA the median PFS … patients with high CYFRA 21-1 the median PFS
and OS was 1.9 and 6.1 compared to 3.4 and 23.8 months for patiens with low CYFRA 21-1 (…

… of patients and did not examine prognostic value in an in-depth manner. In this study, we
measured CYFRA 21-1 levels in 157 patients … the prognostic importance of CYFRA 21-1 levels. …